Abstract

Background: Mesenchymal stem cell (MSC) transplantation has been reported to improve neurological function following neural injury. Many physiological and molecular mechanisms involving MSC therapy-related neuroprotection have been identified.

Methods: A review is presented of articles that pertain to MSC therapy and diverse brain injuries including stroke, neural trauma, and heat stroke, which were identified using an electronic search (e.g., PubMed), emphasize mechanisms of MSC therapy-related neuroprotection. We aim to discuss neuroprotective mechanisms that underlie the beneficial effects of MSCs in treating stroke, neural trauma, and heatstroke.

Results: MSC therapy is promising as a means of augmenting brain repair. Cell incorporation into the injured tissue is not a prerequisite for the beneficial effects exerted by MSCs. Paracrine signaling is believed to be the most important mediator of MSC therapy in brain injury. The multiple mechanisms of action of MSCs include enhanced angiogenesis and neurogenesis, immunomodulation, and anti-inflammatory effects. Microglia are the first source of the inflammatory cascade during brain injury. Cytokines, including tumor necrosis factor-α, interleukin-1β, and interleukin-6, are significantly produced by microglia in the brain after experimental brain injury. The proinflammatory M1 phenotype of microglia is associated with tissue destruction, whereas the anti-inflammatory M2 phenotype of microglia facilitates repair and regeneration. MSC therapy may improve outcomes of ischemic stroke, neural trauma, and heatstroke by inhibiting the activity of M1 phenotype of microglia but augmenting the activity of M2 phenotype of microglia.

Conclusion: This review offers a testable platform for targeting microglial-mediated cytokines in clinical trials based upon the rational design of MSC therapy in the future. MSCs that are derived from the placenta provide a great choice for stem cell therapy. Although targeting the microglial activation is an important approach to reduce the burden of the injury, it is not the only one. This review focuses on this specific aspect.

Keywords

heatstroke, Ischemic stroke, mesenchymal stem cells, neural trauma
1 | INTRODUCTION

1.1 | Neuroinflammation is a hallmark of brain injury

Inflammation is a hallmark of stroke (Lambertsen, Biber, & Finsen, 2012), traumatic brain injury (TBI) (Mannix & Whalen, 2012), and heatstroke pathology (Chen, Lin, & Chang, 2013). The cytokines that modulate tissue injury in ischemic stroke, TBI, spinal cord injury (SCI), or heatstroke, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1, and IL-6, are potential targets for future therapy. The production of these cytokines in greatly increased by microglia in the brain the first 24 hours after experimental stroke (Clausen, Lambertsen, Meldgaard, & Finsen, 2005; Clausen et al., 2008; Hill et al., 1999; Lambertsen, Meldgaard, Ladeby, & Finsen, 2005). Interleukin-1β and TNF-α are produced by a largely segregated population of microglia and infiltrating macrophages after ischemic stroke in mice (Clausen et al., 2008). This has promoted the hypothesis that inhibiting proinflammatory cytokine production may be a therapeutic approach in treating brain injury (Barone & Parsons, 2000). Indeed, according to an observational study that involved 629 consecutive patients with chronic neurological, neuropsychiatric, and clinical impairment after stroke and TBI, the perisplinal administration of etanercept produces clinical improvement (Tobinick, Rodriguez-Romancce, Levine, Ignatowski, & Spengler, 2014). In addition, various drugs or strategies improve outcomes of experimental heatstroke by reducing the overproduction of these proinflammatory cytokines resulting from heat stress (Chen et al., 2013).

1.2 | Microglial activation is involved in brain injury pathology

In contrast to their well-known deleterious roles, TNF-α and IL-6 have also been shown to exhibit neuroprotective properties. In both TNF-deficient mice (Bruce et al., 1996; Gary, Bruce-Keller, Kindy, & Mattson, 1998; Lamberts et al., 2009; Taoufik et al., 2007) and IL-6-deficient mice (Herrmann et al., 2003), infarct sizes were significantly increased following cerebral injury. In addition, TNF-α and IL-6 double-receptor knockout mice had higher mortality rates than did their wild-type controls following heatstroke collapse (Leon, Blaha, & DuBose, 2006). Adult IL-6 knockout mice have also shown to compromise neurogenesis (Bowen, Dempsey, & Vemuganti, 2011). A complete lack of TNF-α or IL-6 might be detrimental to neurogenesis in the adult brain (Monje, Toda, & Palmer, 2003; Vallières, Campbell, Gage, & Sawchenko, 2002). This can be concluded by previous studies that show that an appropriate baseline level of TNF-α or IL-6 is necessary and essential for neurogenesis or host defense, whereas higher levels of TNF-α or IL-6 are detrimental to neurogenesis or host defense.

Microglia are activated rapidly in response to central nervous system injury and produce proinflammatory cytokines, growth factors, reactive oxygen species, nitric oxide, and glutamate (Block & Hong, 2005; Jin, Yang, & Li, 2010; Stolp & Dzitkoiewska, 2009). An appropriate state of microglial activation is necessary and crucial for host normal neurogenesis and defense; however, microglial overactivation results in deleterious and neurotoxic consequences. Proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, which are increasingly expressed during experimental stroke, have a crucial role in the progression of neuronal loss and brain injury (Banati, Gehrmann, Schubert, & Kreutzberg, 1993; Barone et al., 1997; Rothwell, Allan, & Toulmond, 1997).

Recent developments in magnetic resonance (MR) and positron emission tomography (PET) imaging techniques have demonstrated that increased binding of the peripheral benzodiazepine receptor (PBR) PET ligand $^{11}$C-RK1195 is interpreted as a marker of microglial activation and hence neuroinflammation in several brain diseases (Denes et al., 2010). Increases in $^{11}$C-PK11195 binding are found 30 days after stroke in patients, which suggests a contribution of microglial activation to ongoing processes in the ischemic brain (Price et al., 2006). In a rat stroke model, evidence supports a role for microglia as a central mediator in the ongoing processes of stroke damage (Gelosa et al., 2014). In addition, microglial activation is involved in other neurodegenerative disease models, such as Alzheimer’s and Parkinson’s disease (Mosher & Wyss-Coray, 2014; Walker et al., 2014), traumatic brain injury (Chio, Lin, & Chang, 2015), and heatstroke (Chen et al., 2013).

Tumor necrosis factor-alpha levels in both serum and cerebrospinal fluid are found to be significantly elevated in ischemic stroke, traumatic brain injury, and heatstroke (Chen et al., 2013; Chio et al., 2015; Gelosa et al., 2014). Activation of TNF receptor 1 (TNF-R1) is believed to promote proinflammatory and proapoptotic action, astrogliosis, leukocyte extravasation, and disrupted blood–brain barrier (BBB) permeability (McCoy & Tansey, 2008). However, other results have demonstrated that TNF-R1 is required for erythropoietin receptor and vasculoendothelial growth factor expression and protective effects in primary cortical neurons after ischemic and excitotoxic injury (Taoufik et al., 2008).

1.3 | MSC therapy may improve outcomes of brain injury by modulating microglial activation

Mesenchymal stem cells (MSCs) can be derived from different sources, including bone marrow, adipose tissue, the umbilical cord, and the placenta. Currently, clinical trials are being conducted to investigate the therapeutic effects of human MSCs in many cardiovascular and neurodegenerative disorders (Kalladka & Muir, 2014; Mastri, Lin, & Lee, 2014). In addition to their multilineage differentiation potential, MSCs may exert their regenerative effect via the production of multiple paracrine factors (Kalladka & Muir, 2014; Mastri et al., 2014). Production of IL-6, vascular endothelial growth factor (VEGF), hepatocytes growth factor (HGF), brain-derived neurotrophic factors (BDNF), glial-derived neurotrophic factor (GDNF), neurotrophin-3 (NT3), fibroblast growth factor (FGF), and thrombospondins can be promoted by MSCs. It is well known that neural injury results in BBB breakdown and the infiltration of tissue neutrophils and macrophages into damaged brain tissue, which causes microglial activation. In addition, microglia have been promoted as a compelling target for treating infectious and inflammatory diseases of the brain (Chio et al., 2015; Denes et al., 2010; Rock & Peterson, 2006). It is likely that MSC therapy may improve outcomes of brain injury by modulating microglial
activation. Although targeting the microglial activation is an important approach to reduce the burden of the injury, it is not the only one.

1.4 MSCs fulfill the criteria that have been established by the international society of cellular therapy

Mesenchymal stem cells are multipotent, self-renewing cells (Friedenstein, Petrakova, Kurolesova, & Frolova, 1968). They fulfill the following criteria that have been established by the International Society of Cellular Therapy (Dominici et al., 2006): (i) adherence to plastic, (ii) expression of CD105, CD73, and CD90; lack of expression of CD45, CD34, CD14, CD116, CD79a, CD19, and HLA11; and (iii) ability to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro. Due to extensive self-renewal capacity, their ease of isolation, and their presence during young and fetal life, MSCs that are derived from the placenta are an appropriate source for stem cell therapy.

In this review, we collected publications that pertain to MSC therapy and cerebral injury that is caused by stroke, neural trauma, and heat-stroke. In doing so, we emphasized the mechanisms of MSC therapy-related neuroprotection, which were identified using an electronic search (e.g., using PubMed). It reports the feasibility of MSCs to improve neurological function after injury. It focuses on adult injuries such stroke, TBI, and heatstroke. It summarizes the pathophysiology of the injury briefly and offers an overview of MSCs therapeutic approaches.

2 THERAPEUTIC EFFECTS OF MSCS IN ISCHEMIC STROKE

2.1 Neonatal stroke rats or mice

Neonatal stroke occurs frequently in live birth and presents motor dysfunction, cognitive deficits, and epilepsy (Ferriero, 2004; Kirton & de Veber, 2009). However, treatment options are not currently available. The transplantation of MSCs into neonatal animal models of ischemic stroke promotes functional recovery by stimulating neurogenesis, oligodendrogenesis, and axonal remodeling (van Velthoven, Kavelaars, van Bel, & Feijene, 2010a,b; Yasuhara et al., 2008). The beneficial effect of MSC transplantation might involve the augmentation of the secretion of growth and differentiation factors and the fostering of an environment that stimulates both angiogenesis and neurogenesis (van Velthoven et al., 2010b, 2012, 2013) (Table 1). The secretome that has been obtained from MSCs contains several neurotrophic factors, including insulin-like growth factor-1 and brain-derived neurotrophic factor, which are responsible for the protective effects of MSCs that were observed in studies with in vitro and in vivo neuronal injury models (Wei et al., 2009). When compared with adults, it is believed that newborns benefit more from cell therapy because newborns have an increased brain plasticity as well as a different pathophysiology of the injury. In addition, in newborns the microglial activation is more pronounced as microglial activation is present during physiological brain development as well.

2.2 Adult ischemic stroke models

2.2.1 MSC therapy improves outcomes of stroke mainly by secreting paracrine factors

Mesenchymal stem cells have the potential to differentiate into osteoblasts, chondrocytes, adipocytes, hepatocytes, and neurons (Sanchez-Ramos et al., 2000). Although, MSCs are able to pass through the BBB (Kopen, Prockop, &phinney, 1999), MSCs that are transplanted by intracerebral or intravenous routes minimally and selectively migrate to the ischemic boundary sites (Li et al., 2002; Zhao et al., 2002). Considering the small number of MSCs in injured brain tissue, the presence of therapeutic neurotrophic factors that are secreted by MSCs

### TABLE 1 Effects of mesenchymal stem cells (MSCs) therapy on ischemic stroke damage

| Treatment regimens | Main results | References no. |
|--------------------|--------------|----------------|
| 1. Neonatal stroke rats or mice received intranasal or intracerebral injection of MSCs | Decreasing cerebral damage by reducing both overproduction of IL-6 and TNF-α and microgliosis, but stimulating neurogenesis (e.g., increased production of HGF, VEGF, IGF, EGF, 6FGF, IL-10, GDNF, BDNF, NF3, angiopoietin, TGF, and I-CAM 1) | van Velthoven et al. (2010a,b), Yasuhara et al. (2008), van Velthoven et al. (2012, 2013), Wei et al. (2009) |
| 2. Adult stroke rats received intravenous or intracerebral injection of MSCs | Decreasing cerebral damage by stimulating synaptogenesis and vessel density, reducing apoptosis in the ischemic boundary zone, and increasing proliferation of progenitor cells in the subventricular zone. | Wakabayashi et al. (2010), Xu et al. (2010); Bao et al. (2011), Lin et al. (2011); Walker et al. (2010), Wei et al. (2012), Ma et al. (2013), Tang et al. (2014a,b), Cheng et al. (2015) |
| 3. Adult stroke monkeys received intracerebral injection of MSCs | Reducing cerebral damage by stimulating production of IL-10 | Li et al. (2010) |
| 4. Adult stroke patients received intravenous injection of MSCs | Reducing cerebral damage by promoting nerve cell proliferation | Weimann et al. (2003), Bang et al. (2005), Lee et al. (2010) |

MSCs, mesenchymal stem cells; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; IL-10, interleukin-10; VEGF, vascular endothelial growth factor; HGF, hepatocytes growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; NT3, neurotrophin-3; FGF, fibroblast growth factor; IGF-1, insulin-like growth factor; EGF, epidermal growth factor; TGF, transforming growth factor; ICAM-1, intercellular adhesion molecule-1.
apparently confers neuroprotection. This suggests that providing the therapeutic molecules that are secreted by these cells can be neuroprotective (Borlongan, Hadman, Sanberg, & Sanberg, 2004). Although MSCs have been shown to localize only to the injured brain using immunohistochemistry (Chen et al., 2001; Vendrame et al., 2004), intravenously transplanted human MSCs are functionally involved in repair in ischemic stroke rats, possibly by providing human insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (FGF), and neurotrophic neurotrophic factors to the host brain (Wakabayashi et al., 2010). Xu and colleagues (Xu et al., 2010) further suggested that the transplantation of neuronal cells induced from human MSCs improves neurological function after stroke without cell fusion.

2.2.2 | MSC therapy improves outcomes of stroke by stimulating angiogenesis, neurogenesis, and synapse formation

The mechanisms that underlie the beneficial effects of transplanted MSCs include transdifferentiation into the neural lineage as well as the induction of neurogenesis, angiogenesis, and synapse formation in rodents (Kurozumi et al., 2005; Li et al., 2002; Shen et al., 2006; Wislet-Gendebien et al., 2005). Transplantation of MSCs protects against cerebral injury and upregulates IL10 expression in Macaca fascicularis (Li et al., 2010), thereby suggesting the activation of endogenous neurotrophins. Angiogenesis that is induced by MSC transplantation promotes endogenous neurogenesis, which may produce functional recovery after cerebral injury in rats with ischemic stroke (Bao et al., 2011). Both histology and MRI reveal that human umbilical MSCs promote recovery after ischemic stroke in rats (Lin et al., 2011). The beneficial effects of MSC therapy are associated with improved revascularization in ischemic injured tissues.

2.2.3 | MSC therapy attenuates neuronal death by suppressing activated microglia

During the acute phase of cerebral injury, the expression of neuronal and microglial IL-6 is elevated in the injured penumbra (Berti et al., 2002; Block, Peters, & Nolden-Koch, 2000). Direct intrathecal implantation of MSCs results in enhanced neuroprotection. The implantation of MSCs into the injured brain activates resident stem cells niches via an NF kappa B-mediated increase in IL-6 production (Walker et al., 2010). Microglia have also been implicated in the pathogenesis of a number of neurodegenerative diseases, such as stroke, Alzheimer’s disease, dementia, and multiple sclerosis (Danton & Dietrich, 2003). Microglia can defend against brain damage, but excessive or sustained microglia activation can contribute to apoptotic cell death (Ohmi et al., 2003). Bone marrow MSCs result in the suppression of activated microglia and to a delay of neuronal death (Ohmi et al., 2003; Wei, Fraser, Lu, Hu, & Yu, 2012). Human MSCs also stimulate angiogenesis in focal cerebral injury by increasing expression of α-tubulin and angiopoietin 1 and 2 (Ma et al., 2013). MSC treatment reduces the expression of inflammatory cytokines in lipopolysaccharide-activated microglia and subsequently reduces aquaporin-4 expression and apoptosis of astrocytes after cerebral injury (Tang, Cai, et al., 2014, Tang, Liu, et al., 2014). In addition, the survival and function of transplanted MSCs after focal cerebral injury can be enhanced by melatonin pretreatment (Tang et al., 2014b). Both neurological deficit and brain edema and infarct volume are significantly decreased postischemic stroke with MSC treatment via the tail vein (Tang et al., 2014a). MSCs also protect against brain injury in the mouse by stimulating the production of TGF-β (transforming growth factor), but reduce proinflammatory cytokines (e.g., IL-1, TNF-α) (Cheng et al., 2015). Thus, it appears that MSCs improve outcomes of ischemic stroke in animal models by stimulating neurotrophic factors production and endogenous neurogenesis and modulating neuroinflammation.

2.3 | Stroke patients

Systemic delivery of MSCs has also been shown to be a feasible and safe therapy for treating ischemic stroke patients (Tang et al., 2014b). Long-term follow-up data further indicate a contribution of transplanted MSCs to Purkinje neurons in human adult brains (Bang, Lee, Lee, & Lee, 2005; Lee et al., 2010; Weimann, Charlton, Brazelton, Hackman, & Blau, 2003). Both clinical (Bang et al., 2005; Cheng et al., 2015; Tang et al., 2014a) and experimental (Lee et al., 2015) studies demonstrate that the outcomes of ischemic stroke in patients and rodents are greatly improved by MSC therapy. Furthermore, earlier administration of MSCs produces an improved functional recovery, survival rate, stroke recurrences, or adverse effects.

A more recent report has shown that CD4+ CD28- T cells (also called CD28 null cells) are increased in the clinical setting of acute ischemic stroke (Tuttolomondo et al., 2015). Among these T cells, CD28 null cells produce high amounts of γ-interferon and TNF-α and thus may have a direct pathogenetic role in neuronal damage. It is not known whether the peripheral frequency of CD28 null cells in acute ischemic stroke can be affected by MSC therapy.

3 | THERAPEUTIC EFFECTS OF MSCS IN NEURAL TRAUMA

3.1 | Microglial activation as a biomarker for neural trauma

Mechanical injury to the brain or spinal cord results in glutamate excitotoxicity, BBB disruption, ischemia, mitochondria dysfunction, apoptotic and necrotic cell death, and inflammation (Mannix & Whalen, 2012). Secondary injury following TBI (traumatic brain injury) includes microglial activation (Davalos et al., 2005). Microglial activation occurs as early as 72 hr after injury in human TBI patient and persists for years after injury. Activated M1 phenotype microglia causes the overexpression of both proinflammatory cytokines (such as IL-1β, IL-6, and TNF-α) and other neurotoxic products (such as reactive oxygen species [ROS] and reactive nitrogen species [RNS]). M2 phenotype of microglia is able to release neuroprotective substances, including anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist) and
MSCs is shown to improve recovery after SCI in rats (Cantinieaux et al., 2013). Indeed, the systemic or intraspinal cord administration of MSCs significantly attenuates SCI in rodents (Chopp et al., 2000; Hu et al., 2010; Kao, Chen, Chio, & Lin, 2008; Lu, Jones, & Tuszynski, 2005; Okano et al., 2003; Satake, Lou, & Lenke, 2004), dogs (Penha et al., 2014), rabbits (Moon et al., 2014), monkeys (Deng et al., 2006), or patients (Arien-Zakay et al., 2014; Cheng et al., 2014; Jiang et al., 2013; Mendonça et al., 2014). MSCs are beneficial in reversing the neurological motor deficits of SCI, even when infused 5 days after injury (Saporta et al., 2003). Human MSCs are observed in the injured areas but not in noninjured areas, of rat spinal cords, and are never seen in corresponding areas of spinal cord of noninjured animals. Immunohistochemical examination reveals that transplanted MSCs survive in the host spinal cord for at least 3 weeks after transplantation but disappear by 5 weeks (Nishio et al., 2006). It is well known that MSCs secrete a variety of molecules that are beneficial in treating SCI (Cantinieaux et al., 2013). Indeed, the systemic administration of conditioned medium (or secretome) from MSCs is shown to improve recovery after SCI in rats (Cantinieaux et al., 2013). In addition, in TBI mice, TBI rats, or TBI patients, intravenous or intrathecal administration of MSCs (Arien-Zakay et al., 2014; Chen et al., 2014; Lu et al., 2002; Nichols et al., 2013; Wang et al., 2013; Zanier et al., 2011; Zhang et al., 2013, 2015) significantly improves the outcomes of TBI. The systemic injection of the secretome of cultured MSCs also improves the outcomes of TBI in rats (Chang et al., 2013). The transplantation of hypoxia-preconditioned MSCs improves infracted heart function via the enhanced survival of implanted cells and angiogenesis (Hu et al., 2008). It seems that while MSCs exhibit a prominent multilineage differentiation potential, the MSCs-derived mediators contribute to cytoprotection, angiogenesis, tissue repair, and alleviation of inflammation during neural injury (Mastri et al., 2014). Cell incorporation into the vessels or neurons is not a prerequisite for the beneficial effects that are exerted by MSCs. MSCs may improve the outcomes of neural injury by modulating multiple mechanisms, such as the secretion of trophic factor and immune function (Kalladka & Muir, 2014).

### TABLE 2 Effects of MSCs therapy on spinal cord injury (SCI) or traumatic brain injury (TBI)

| Treatment regimens | Main results | References no. |
|-------------------|-------------|----------------|
| 1. SCI rats or SCI mice received intravenous or intraspinal cord injection of MSCs | Reducing spinal cord damage or neurological deficits by stimulating production of both GDNF and VEGF and neurofilament fibers and axonal growth (angiogenesis and neurogenesis). | Chopp et al. (2000), Okano et al. (2003), Satake et al. (2004), Lu et al. (2005), Kao et al. (2008); Hu et al. (2010) |
| 2. SCI rats received intravenous injection of MSCs-derived secretome | In vitro, secretome obtained from MSCs protects neurons from apoptosis, activates macrophages, and is proangiogenic. In vivo, MSCs secretome improves motor recovery. | Cantinieaux et al. (2013) |
| 3. SCI dogs, rabbits, or monkeys received intraspinal cord injection of MSCs | Reducing spinal cord damage or neurological deficits by stimulating both de novo neurogenesis and production of BDNF | Deng et al., 2006; Penha et al., 2014; Moon et al., 2014 |
| 4. SCI patients received intrathecal or intraspinal cord injection of MSCs | Reducing spinal cord damage or neurological deficits by stimulating production of both GDNF and VEGF and neurofilament fibers and axonal growth (angiogenesis and neurogenesis). | Jiang et al., 2013; Mendonça et al., 2014; Cheng et al., 2014 |
| 5. TBI rats or mice received intravenous, intra-arterial, or intracerebroventricular injection of MSCs | Reducing cerebral damage or neurological deficits by stimulating production of BDNF, NGF, VEGF, and IL-10, angiogenesis, and neurogenesis. | Lu et al. 2002; Zanier et al., 2011; Zhang et al., 2013, 2015; Nichols et al., 2013; Chen et al., 2014; Arien-Zakay et al., 2014 |
| 6. TBI rats received intravenous injection of MSCs-derived secretome | Reducing cerebral damage or neurological deficits by secreting bioactive factors, including HGF and VEGF | Chang et al., 2013 |
| 7. TBI patients received intrathecal injection of MSCs | Reducing cerebral damage or neurological deficits | Wang et al., 2013 |

Please see the legends of Table 1 for the explanation of abbreviations.
Heat-tolerant rats exhibit low levels of both IL-1β and TNF-α mRNA in the hypothalamus as well as high corticosterone levels in serum (Hu et al., 2008). In contrast, heat-intolerant rats present higher hypothalamic levels of both IL-1β and TNF-α mRNAs, but lower serum corticosterone level (Michel et al., 2007). Hypothalamic levels of IL-6, TNF-α, IL-1β, and nitrite in the hypothalamus were upregulated by heatstroke (Hsu, Chen, Lin, & Yung, 2014). It has been suggested that the inflammatory response in the acute phase of tissue injury may be related to aggravating tissue injury; however, in the later phase, these inflammatory mediators may contribute to tissue repair (Kadhkim, Duchateau, & Sébire, 2008). Cytokines, such as IL-6 and TNF-α, may be essential at physiological levels for the maintenance of the endogenous neurogenesis in the brain (Bowen et al., 2011). Neither lack nor excess of IL-6 or TNF-α is beneficial for homeostasis of the inflammatory mechanisms.

5.1 | Resuscitation from experimental heatstroke by transplantation of human umbilical cord blood cells (HUCBC) or HUCBC-derived CD34+ cells

The plasma levels of inflammatory cytokines, such as IL-6 and TNF-α, are elevated in humans (Bouchama, Al-Sedairy, Siddiqui, Shal, & Rezeig, 1993; Chang, 1993), rats, and rabbits (Lin, Kao, Su, & Hsu, 1994; Lin, Liu, & Yang, 1997) and mice with heatstroke (Tseng, Chen, Lin, & Lin, 2005; Chen et al., 2006), and systemic inflammation (Chen et al., 2006; Liu et al., 2009). The administration of HUCBC increases the serum levels of IL-10 and decreases the levels of TNF-α during heatstroke (Liu et al., 2009; Tseng et al., 2014).

It has been estimated that approximately 2% of HUCBC are positive for CD34 expression (Bender et al., 1991). CD34+ cells transplantation also attenuates the outcomes of heatstroke by reducing TNF-α production in serum, stimulating IL-10 production in serum, and stimulating production of GDNF in brain (Chen et al., 2007; Hwang et al., 2008).

### TABLE 3 Effects of mesenchymal stem cells (MSCs) therapy on heatstroke-induced cerebral ischemic damage

| Treatment regimens | Main results | References no. |
|--------------------|--------------|----------------|
| 1. Heatstroke rats received intravenous or intracerebroventricular injection of HUCBCs | MSCs attenuate cerebral ischemic damage by reducing overproduction of TNF-α, IL-1β, and IL-6, but stimulating production of IL-10. | Chen et al. (2005) Chen et al. (2006) Liu et al. (2009) |
| 2. Heatstroke rats received intravenous injection of HICBC-derived CD34+ cells | MSCs reduce cerebral ischemic damage by reducing overproduction of both TNF-α and ICAM-1, but stimulating production of IL-10. | Hwang et al. (2008) Chen et al. (2007) Tseng et al. (2014) |
| 3. Heatstroke rats received subcutaneous injection of granulocyte-colony stimulating factor | The factor attenuates cerebral ischemic damage by reducing overproduction of both TNF-α and ICAM-1, but stimulating production of IL-10, EPOs, GDNF, and VEGF. | Yung et al. (2011) |
| 4. Heatstroke mice received intravenous injection of human dental pulp-derived stem cells or HUCBCs | MSCs attenuate cerebral ischemic damage by reducing overproduction of TNF-α, intercellular adhesion molecule 1, and oxidative damage markers, but promoting both hypothalamo–pituitary–adrenocortical axis activity and IL-10 production. | Tseng et al. (2014) Tseng et al. (2015) |

HUCBCs, human umbilical cord blood cells.

Please see the legends of Table 1 for the explanation of abbreviations.

5.2 | The potential use of granulocyte-colony stimulating factor (G-CSF) as a prophylactic agent for heatstroke

G-CSF is a polypeptide that promotes the mobilization of stem cells into peripheral blood (Lu & Xiao, 2006) and results in a reduction in mortality, infarct volume, and neurological deficits after cerebral ischemia in heatstroke rats (Lu & Xiao, 2006). Preconditioning with G-CSF attenuates heatstroke-induced hypothalamic apoptosis and neuronal damage by stimulating GDNF and VEGF overproduction in hypothalamus, thereby reducing levels of TNF-α, increasing levels of IL-10, and stimulating the expression of endothelial progenitor cells in the serum of rats (Yung et al., 2011).

5.3 | Transplantation of human dental pulp-derived stem cells protects against heatstroke

Human dental pulp-derived stem cells are self-renewing stem cells that reside within the perivascular niche of the dental pulp (Gronythos et al., 2002). They enhance recovery of focal cerebral injury in rats (Inoue et al., 2013). Human dental pulp-derived stem cells are also shown to attenuate ischemia and oxidative damage to the hypothalamus and the overproduction of systemic response syndrome molecules, including TNF-α and ICAM-1, in the peripheral blood stream in heatstroke mice (Tseng, Chen, Lin, & Lin, 2015). When considering the data presented herein, it appears that human MSCs may improve outcomes of heatstroke by reducing the overproduction of systemic response syndrome molecules as well as multiple-organ dysfunction or failure (Table 3).

Therefore, it can be concluded that some spontaneous but not extensive recovery (or increased endogenous neurogenesis) is typical following brain injury caused by stroke, neural trauma, and heatstroke. Exogenous cell therapy is promising as a means of augmenting brain repair by modulating microglial activation as depicted in Fig. 1. As mentioned in the foremost section, the proinflammatory M1
phenotype of microglia is associated with tissue destruction, whereas the anti-inflammatory M2 phenotype of microglia facilitates repair and regeneration. Therefore, MSC therapy may improve outcomes of ischemic stroke, neural trauma, and heatstroke by inhibiting the activity of M1 phenotype of microglia but augmenting the activity of M2 phenotype of microglia.

6 | CONCLUSIONS

6.1 | The targeting of microglial activation in clinical trials as a rational design of NSC therapy in the future

During ischemic stroke, after brain trauma, and during heatstroke, the intrinsic inflammatory mechanisms of the brain as well as those of the peripheral blood stream are mediated by the release of pro-and anti-inflammatory cytokines and chemokines. According to a more recent review (Chio et al., 2015; Tuttolomondo, Pecoraro, & Pinto, 2014), microglia are the first source of the inflammatory cascade during brain ischemia and after brain trauma. Additionally, an important mediator of this inflammatory event is TNF-α. Etanercept, a TNF-α antagonist, which has been used therapeutically in animal models of ischemic stroke and neural damage (Kinnaird et al., 2004). In addition, various drugs or strategies have improved the outcomes of experimental heatstroke by reducing the overproduction of these proinflammatory cytokines in both the brain and the peripheral blood stream (Chen et al., 2013). Although some spontaneous recovery (due to endogenous neurogenesis) in humans is thought to contribute to repair, exogenous MSC therapy is promising as a means of augmenting brain repair. MSCs, when administered systemically, are observed in the injured brain areas but not in noninjured brain areas and are never seen in corresponding brain areas of noninjured animals (Nishio et al., 2006). Nevertheless, paracrine signaling, rather than cell incorporation into vessels or neurons, is a prerequisite for the beneficial effects that are exerted by MSCs (Kinnaird et al., 2004). The multiple mechanisms of action of MSCs include enhanced angiogenesis and neurogenesis (by the secretion of trophic factors), immunomodulation, and anti-inflammatory effects (Kalladka & Muir, 2014). Cytokines, including TNF-α, IL-1, and IL-6, are greatly produced by microglia in the brain after experimental stroke (Claesen et al., 2005, 2008; Hill et al., 1999; Lamberty et al., 2005). Appropriate baseline levels of TNF-α or IL-6 are necessary and essential for neurogenesis or host defense, whereas higher levels of TNF-α or IL-6 are detrimental to neurogenesis or host defense (please see the Introduction). The appropriate level of microglial activation is necessary and crucial for normal neurogenesis and host defense, whereas microglial overactivation results in deleterious and neurotoxic consequences (please see the Introduction section). The exogenous administration of MSCs may promote tissue repair by stimulating trophic factor release and endogenous neurogenesis (Chamberlain, Fox, Ashton, & Middleton, 2007; Chen, Tredget, Wu, & Wu, 2008; Phinney & Prockop, 2007). The expression of prosurvival and proangiogenic markers in MSCs can be enhanced by hypoxic preconditioning (Chacko et al., 2010). This review offers a testable platform for the targeting of microglial activation in clinical trials that are based upon rational design of MSC therapy in the future.

It is most probable that the central concern that is considered in this review is that MSCs may exert their neuroprotective effects mainly by modulating the production of both cytokines and neurotrophic factors. In addition, immunosuppression of allogenic MSC transplantation after neural injury improves graft survival and beneficial outcomes in rats (Torres-Espin, Redondo-Castro, Hernandez, & Navarro, 2015). Conversely, the intravenous, intranasal, or intracerebral administration of MSCs is found to be beneficial in treating neurological damage.
To produce a similar beneficial effect, the intravenous route injection needs a lesser dosage than does the intracerebral route injection, suggesting the central action of MSCs. Additionally, compared to MSCs therapy adopted postinjury, pretreatment regimens of MSCs has significantly better beneficial effects. However, expansion of MSCs without fetal bovine serum is a big problem during different pretreatment regimens and preparation of MSCs. Nevertheless, because substances that are administered via the peripheral blood stream are able to reach multiple organs (including brain tissues) during diseased conditions, intravenous route injection is the most practical approach for cell therapy in general.

6.2 | MSCs that are derived from the placenta may be the most practical for use in the treatment of brain ischemic injury

To our knowledge, the in vitro characteristics and in vivo potency of placenta-derived MSCs have not been well explored or investigated thoroughly. In addition, future studies are warranted for the clinical application of placenta-derived MSCs in stroke, TBI, heatstroke, and other neurodegenerative diseases. In our opinion, MSCs fulfill the criteria that have been set by the International Society of Cellular Therapy (as described in the Introduction section). Therefore, in comparison with other types of stem cells, MSCs are the most practical to use in the case of brain ischemic injury.

FUNDING INFORMATION

Ching-Ping Chang and Mao-Tsun Lin have been supported by Ministry of Science and Technology of the Republic of China, Taipei, Taiwan (no. MOST 104-2314-B-218-001-MY3; CMFHT 10401).

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

REFERENCES

Arien-Zakay, H., Gingberg, G., Nagler, A., Cohen, G., Liraz-Zaltsman, S., Tremborler, V., ..., Shoham, E. (2014). Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury. Journal of Neurotrauma, 31, 1405–1416.

Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993). Cytotoxicity of microglia. Glia, 7, 111–118. Review.

Bang, O. Y., Lee, J. S., Lee, P. H., & Lee, G. (2005). Autologous mesenchymal stem cell transplantation in stroke patients. Annals of Neurology, 57, 874–882.

Bao, X., Wei, J., Feng, M., Lu, S., Li, G., Dou, W., ..., Wang, R. (2011). Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Research, 1367, 103–113.

Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Willette, R. N., ..., Feuerstein, G. Z. (1997). Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke, 28, 1233–1244.

Barone, F. C., & Parsons, A. A. (2000). Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opinion on Investigational Drugs, 9, 2281–2306. Review.

Bender, J. G., Unverzagt, K. L., Walker, D. E., Lee, W., Van Epps, D. E., Smith, D. H., ..., To, L. B. (1991). Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood, 77, 2591–2596.

Berti, R., Williams, A. J., Moffett, J. R., Hale, S. L., Velarde, L. C., Elliott, P. J., ..., Tortella, F. C. (2002). Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. Journal of Cerebral Blood Flow and Metabolism, 22, 1068–1079.

Block, M. L., & Hong, J. S. (2005). Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Progress in Neurobiology, 76, 77–98.

Block, F., Peters, M., & Nolden-Koch, M. (2000). Expression of IL-6 in the ischemic penumbra. NeuroReport, 11, 963–967.

Borlongan, C. V., Hadman, M., Sanberg, C. D., & Sanberg, P. R. (2004). Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke, 35, 2385–2389.

Bouchama, A., Al-Sedairy, S., Siddiqi, S., Shail, E., & Rezeig, M. (1993). Elevated pyrogenic cytokines in heatstroke. Chest, 104, 1498–1502.

Bowan, K. K., Dempsey, R. J., & Vemuganti, R. (2011). Adult interleukin-6 knockout mice show compromised neurogenesis. NeuroReport, 22, 126–130.

Bruce, A. J., Boling, W., Kindy, M. S., Peschon, J., Kraemer, P. J., Carpenter, M. K., ..., Mattson, M. P. (1996). Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nature Medicine, 2, 788–794.

Cantinieaux, D., Quertainmont, R., Blacher, S., Rossi, L., Wanet, T., Noël, A., ..., Franzen, R. (2013). Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: An original strategy to avoid cell transplantation. PLoS ONE, 8, e69515.

Chacko, S. M., Ahmed, S., Selvendiran, K., Kuppusamy, M. L., Khan, M., & Kuppusamy, P. (2010). Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. American Journal of Physiology: Cell Physiology, 299, C1562–C1570.

Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007). Concise review: mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25, 2739–2749.

Chang, D. M. (1993). The role of cytokines in heatstroke. Immunological Investigations, 22, 553–561.

Chang, C. P., Chio, C. C., Cheong, C. U., Chao, C. M., Cheng, B. C., & Lin, M. T. (2013). Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clinical Science (Lond), 124, 165–176.

Chen, S. H., Chang, F. M., Chang, H. K., Chen, W. C., Huang, K. F., & Lin, M. T. (2007). Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke. Shock, 27, 663–71.

Chen, S. H., Chang, F. M., Tsai, Y. C., Huang, K. F., & Lin, M. T. (2005). Re-suscitation from experimental heatstroke by transplantation of human umbilical cord blood cells. Critical Care Medicine, 33, 1377–1383.

Chen, S. H., Chang, F. M., Tsai, Y. C., Huang, K. F., Lin, C. L., & Lin, M. T. (2006). Infusion of human umbilical cord blood cells protect against cerebral ischemia and damage during heatstroke in the rat. Experimental Neurology, 199, 67–76.

Chen, S. H., Lin, M. T., & Chang, C. P. (2013). Ischemic and oxidative damage to the hypothalamus may be responsible for heatstroke. Current Neuropharmacology, 11, 129–140 (various strategies improve outcomes of heat stroke by inhibiting overproduction of proinflammatory cytokines).

Chen, J., Sanberg, P. R., Li, Y., Wang, L., Lu, M., Willing, A. E., ..., Chopp, M. (2001). Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke, 32, 2682–2688.

Chen, L., Tredget, E. E., Wu, P. Y., & Wu, Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells...
and enhance wound healing. *PloS ONE*, 3, e1886. (paracrine factors of MSCs enhance wound healing).

Chen, S. H., Wang, J. J., Chen, C. H., Chang, H. K., Lin, M. T., Chang, F. M., ... Chio, C. C. (2014). Umbilical cord blood-derived CD34+ cells improve outcomes of traumatic brain injury in rats by stimulating angiogenesis and neurogenesis. *Cell Transplantation*, 23, 959–979.

Cheng, H., Liu, X., Hua, R., Dai, Q., Wang, X., Gao, J., & An, Y. (2014). Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. *Journal of Translational Medicine*, 12, 253.

Cheng, Q., Zhang, Z., Zhang, S., Yang, H., Zhang, X., Pan, J., ... Xu, Y. (2015). Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. *Brain Research*. 1594, 293–304.

Chio, C. C., Lin, M. T., & Chang, C. P. (2015). Microglia activation as a compelling target for treating acute traumatic brain injury. *Current Medicinal Chemistry*, 22, 759–770.

Chopp, M., Zhang, X. H., Li, Y., Wang, L., Chen, J., Lu, D., ... Rosenblum, M. (2000). Spinal cord injury in rat: Treatment with bone marrow stromal cell transplantation. *NeuroReport*, 11, 3001–3005.

Claussen, B. H., Lambertsen, K. L., Babcock, A. A., Holm, T. H., Dagnaes-Hansen, F., & Finsen, B. (2008). Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. *Journal of Neuroinflammation*, 5, 46.

Claussen, B. H., Lambertsen, K. L., Meldgaard, M., & Finsen, B. (2005). A quantitative in situ hybridization and polymerase chain reaction study of microglial-macrophage expression of interleukin-1beta mRNA following permanent middle cerebral artery occlusion in mice. *Neuroscience*, 132, 879–892.

Danton, G. H., & Dietrich, W. D. (2003). Inflammatory mechanisms after ischemia and stroke. *Journal of Neuropathology and Experimental Neurology*, 62, 127–136. Review.

Davalos, D., Gutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., ... Gan, W. B. (2005). ATP mediates rapid microglial response to local brain injury in vivo. *Nature Neuroscience*, 8, 752–758.

Denes, A., Thornton, P., Rothwell, N. J., Allan, S. M. (2010). Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. *Brain, Behavior, and Immunity*, 24, 708–723.

Deng, Y. B., Liu, X. G., Liu, Z. G., Liu, X. G., Liu, Z. G. & Liu, X. L. (2006). Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: Evidence from a study in rhesus monkeys. *Cytotherapy*, 8, 210–214.

Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., ... Horvitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, 8, 315–317.

Ferriero, D. M. (2004). Neonatal brain injury. *New England Journal of Medicine*, 351, 1985–1995. Review.

Friedenstein, A. J., Petrikova, K. V., Kurolesova, A. I., & Frolova, G. P. (1968). Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation*, 6, 230–247.

Gary, D. S., Bruce-Keller, A. J., Kindy, M. S., & Mattson, M. P. (1998). Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. *Journal of Cerebral Blood Flow and Metabolism*, 18, 1283–1287.

Gelosa, P., Lecca, D., Fumagalli, M., Wypych, D., Pignieri, A., Cimino, M., ... Sironi, L. (2014). Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. *Journal of Cerebral Blood Flow and Metabolism*, 34, 979–988.

Gronthos, S., Brahim, J., Li, W., Fisher, L. W., Cerman, N., Boyde, A., ... Shi, S. (2002). Stem cell properties of human dental pulp stem cells. *Journal of Dental Research*, 81, 531–535.

Hernandez-Ontiveros, D. G., Tajiri, N., Acosta, S., Giunta, B., Tan, J., & Borlongan, C. V. (2013). Microglia activation as a biomarker for traumatic brain injury. *Frontiers in Neurology*, 4, 30.
Taoufik, E., Petit, E., Divoux, D., Tseveleki, V., Mendoza, M., Roberts, M. L., ... Probert, L. (2008). TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proceedings of the National Academy of Sciences of the United States of America, 105, 6185–6190.

Taoufik, E., Valable, S., Mülter, G. J., Roberts, M. L., Divoux, D., Tinel, A., ... Probert, L. (2007). FIPIL(3) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. Journal of Neuroscience, 27, 6633–6646.

Tobinick, E., Rodriguez-Romance, H., Levine, A., Ignatowski, T. A., & Spengler, R. N. (2014). Immediate neurological recovery following periischemic etanercept years after brain injury. Clinical Drug Investigation, 34, 361–366. (Etanercept improves outcomes of brain injury).

Torres-Espin, A., Redondo-Castro, E., Hernandez, J., & Navarro, X. (2015). Immunosuppression of allogenic mesenchymal stem cells transplantation after spinal cord injury improves graft survival and beneficial outcomes. Journal of Neurotrauma, 32, 367–380.

Tseng, L. S., Chen, S. H., Lin, M. T., & Lin, Y. C. (2014). Umbilical cord blood-derived stem cells improve heat tolerance and hypothalamic damage in heat stressed mice. BioMed Research International, 2014, 685683.

Tseng, L. S., Chen, S. H., Lin, M. T., & Lin, Y. C. (2015). Transplantation of human dental pulp-derived stem cells protects against heat stroke in mice. Cell Transplantation, 24, 921–937.

Tuttolomondo, A., Pecoraro, R., Casuccio, A., Di Raimondo, D., Butta, C., Clemente, G., ... Pinto, A. (2015). Peripheral frequency of CD4+ CD28- cells in acute ischemic stroke: Relationship with stroke subtype and severity markers. Medicine (Baltimore), 94, e813.

Tuttolomondo, A., Pecoraro, R., & Pinto, A. (2014). Studies of selective TNF inhibitor in the treatment of brain injury from stroke and trauma: A review of the evidence to date. Drug Design, Development and Therapy, 8, 2221–2239. (Microglia are the first source of the inflammatory cascade during brain ischemia and after brain trauma).

Vallières, L., Campbell, I. L., Gage, F. H., & Sawchenko, P. E. (2002). Reduced expression of neurotrophic factors in a rat focal cerebral ischemia model. Stroke, 33, 9603–9611.

van Velthoven, C. T., Kavelaars, A., van Bel, F., & Feijene, C. J. (2010a). Repeated mesenchymal stem cell treatment after neonatal hypoxic-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. Journal of Neuroscience, 30, 9603–9611.

van Velthoven, C. T., Kavelaars, A., van Bel, F., & Feijene, C. J. (2010b). Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligoden-drocyte regeneration. Brain, Behavior, and Immunity, 24, 387–393 (MSC after hypoxic-ischemic preconditioning have better beneficial effects).

van Velthoven, C. T., Sheldon, R. A., Kavelaars, A., Derugin, N., Vekler, Z. S., Willemen, H. L., ... Ferriero, D. M. (2013). Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke, 44, 1426–1432.

van Velthoven, C. T., van de Looij, Y., Kavelaars, A., Zijlstra, J., van Bel, F., Huppi, P. S., ... Heijnen, D. J. (2012). Mesenchymal stem cells restore cortical re-wiring after neonatal ischemia in mice. Annals of Neurology, 71, 785–796.

Vendrame, M., Cassidy, J., Newcomb, J., Butler, T., Pennypacker, K. R., Zigova, T., ... Willing, A. E. (2004). Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke, 35, 2390–2395.

Wakabayashi, K., Nagai, A., Sheikh, A. M., Shiota, Y., Narantuya, D., Watanabe, T., ... Yamaguchi, S. (2010). Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. Journal of Neuroscience Research, 88, 1017–1025.

Walker, F. R., Beynon, S. B., Jones, K. A., Zhao, Z., Kongsui, R., Cairns, M., & Nilsson, M. (2014). Dynamic structural remodeling of microglia in health and disease: A review of the models, the signals and the mechanisms. Brain, Behavior, and Immunity, 37C, 1–14.

Walker, P. A., Harting, M. T., Jimenez, F., Shah, S. K., Pati, S., Dash, P. K., & Cox, C. S. Jr (2010). Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFκappaB-mediated increase in interleukin-6 production. Stem Cells and Development, 19, 867–876.

Wang, S., Cheng, H., Dai, G., Wang, X., Hua, R., Liu, X., ... An, Y. (2013). Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. Brain Research, 1532, 76–84.

Wei, X., Du, Z., Zhao, L., Feng, D., Wei, G., He, Y., ... Du, Y. (2009). IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells, 27, 478–488.

Wei, L., Fraser, J. L., Lu, Z. Y., Hu, X., & Yu, S. P. (2012). Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiology of Diseases, 46, 635–645.

Weimann, J. M., Chariton, C. A., Brazelton, T. R., Hackman, R. C., & Blau, H. M. (2003). Contribution of transplanted bone marrow cells to purkinje neurons in human adult brains. Proceedings of the National Academy of Sciences of the United States of America, 100, 2088–2093.

Wislet-Gendebien, S., Hans, G., Leprince, P., Rigo, J. M., Moonen, G., & Register, B. (2005). Plasticity of cultured mesenchymal stem cells: Switch from nestin-positive to excitable neuron-like phenotype. Stem Cells, 23, 392–402.

Xu, H., Miki, K., Ishibashi, S., Inoue, J., Sun, L., Endo, S., ... Mizusawa, H. (2010). Transplantation of neuronal cells induced from human mesenchymal stem cells improves neurological functions after stroke without cell fusion. Journal of Neuroscience Research, 88, 3598–3609.

Yasuhara, T., Hara, K., Maki, M., Mays, R. W., Deans, R. J., Hess, D. C., ... Borlongan, C. V. (2008). Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. Journal of Cerebral Blood Flow and Metabolism, 28, 1804–1810.

Yung, M. C., Hsu, C. C., Kang, C. Y., Lin, C. L., Chang, S. L., Wang, J. J., ... Chen, S. H. (2011). A potential for granulocyte-colony stimulating factor for use as a prophylactic agent for heatstroke in rats. European Journal of Pharmacology, 661, 109–117.

Zanier, E. R., Montinaro, M., Viganò, M., Villa, P., Fumagalli, S., Pischiiuta, F., ... De Simoni, M. G. (2011). Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma. Critical Care Medicine, 39, 2501–2510.

Zhao, L. R., Duan, W. M., Reyes, M., Keene, C. D., Verfaillie, C. M., & Low, W. (2012). FLIP(L) protects neurons against in vivo ischemia. Proceedings of the National Academy of Sciences of the United States of America, 109, 6185–6190.

Zhou, L. R., Duan, W. M., Reyes, M., Keene, C. D., Verfaillie, C. M., & Low, W. C. (2002). Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Experimental Neurology, 174, 11–20.

How to cite this article: Hsuan, Y. C.-Y., Lin, C.-H., Chang, C.-P. and Lin, M.-T. (2016), Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. Brain and Behavior, 6: 1–11. e00526, doi: 10.1002/brb3.526.